Skip to content
  1. Home
  2. Latest news
  3. Johnson & Johnson debuts a groundbreaking R&D facility in the San Francisco Bay Area
Johnson-and-Johnson-Debuts-a-Groundbreaking-R-and-D-Facility-in-the-San-Francisco-Bay-Area-0922.png

Johnson & Johnson debuts a groundbreaking R&D facility in the San Francisco Bay Area

Take a look inside the new cutting-edge hub for medical innovation where company scientists and other researchers will collaborate to help find solutions for some of the world’s toughest health challenges.

The new research site, located near the Birthplace of Biotechnology, will be home to scientists focused on finding new solutions for everything from infectious diseases to retinal diseases, using such cutting-edge technologies as gene and RNA therapies and advanced data science.

And thanks to its Bay Area address, the new site will also enable Silicon Valley healthcare entrepreneurs and other researchers to collaborate with company scientists to help advance the next great healthcare breakthroughs.

Watch this drone video for an inside look at the new healthcare innovation hub.

hqdefault.jpg

Check out more innovation in action

Learn how Johnson & Johnson is working to find solutions for some of the world’s toughest health challenges.

More from Johnson & Johnson

Terra Kremer, Ph.D., is on a mission to create self-sterilizing surgical tools

Since its launch, Johnson & Johnson has focused on helping make surgeries safer. Learn how this analytical microbiologist and her team are continuing in that tradition with a digital app that aims to change the way medical devices are designed and sterilized.

What is lupus?

Up to 5 million people worldwide live with this complex autoimmune condition, which is more prevalent in women and has a greater disease severity in Latin Americans and patients of African ancestry. Learn how Johnson & Johnson is working to innovate treatments for autoimmune diseases.

This scientist develops targeted treatments for cancer—here’s what drives and inspires him

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.